Defitelio - direct healthcare professional communication (DHPC)

defibrotide

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Direct healthcare professional communication (DHPC): Defitelio (defibrotide): Do not use for prophylaxis of veno-occlusive disease (VOD) after post-hematopoietic stem-cell transplantation (HSCT)

Key facts

• Medicine name:
  Defitelio
• Active substance:
  defibrotide
• Therapeutic area (MeSH):
  Hepatic Veno-Occlusive Disease
• Procedure number:
  EMEA/H/C/004093/II/0030
• Regulatory outcome:
  Maintenance
• DHPC type:
  • Lack of effect
  • Safety signal
• Human ATC codes:
  B01AX01
• Dissemination date:
  13/06/2022